AstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...

AstraZeneca and Daiichi Sankyo's HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) already has ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter.

Allworth Financial LP boosted its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 12.9% in the fourth quarter, ...

Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

The FDA makes furthering moves in SCLC, ovarian, and breast cancers, and the value of remote clinical pharmacists is explored in community oncology.

India's pharmaceutical market is witnessing a surge in new drug launches, particularly in the oncology segment, fueled by a ...

Enhertu, a cancer drug by AstraZeneca, was the top-selling new drug in 2024 with sales of nearly Rs 58 crore. Over 3,100 new ...

The approach requires balance, however. There is the risk of increased AEs, as well as financial toxicity. Friedlander shared ...